Max Chat
Calendrier des promotions Fennec Pharmaceuticals Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.Paramètres de base
IPO date
2001-06-05
ISIN
CA31447P1009
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
Grade
Sous-estimation
| Nom | Signification | Grade |
| P/S | 3.54 | 5 |
| P/BV | -28.63 | 0 |
| P/E | 0 | 0 |
Efficacité
| Nom | Signification | Grade |
| ROA | -1.21 | 0 |
| ROE | 5.09 | 2 |
| ROIC | 0 | 0 |
Dividendes
| Nom | Signification | Grade |
| Rendement en dividendes | 0 | 0 |
| DSI | 0 | 0 |
| Croissance moyenne du dividende | 0 | 0 |
Devoir
| Nom | Signification | Grade |
| Debt/EBITDA | 5.37 | 0 |
| Debt/Ratio | 0.4303 | 10 |
| Debt/Equity | -8.65 | 10 |
Impulsion de croissance
| Nom | Signification | Grade |
| Rentabilité Revenue, % | 27863.53 | 10 |
| Rentabilité Ebitda, % | -120 | 0 |
| Rentabilité EPS, % | -97.89 | 0 |
paper.price.prices
| Prix | Common.min. | Common.max. | Changement | paper.changes_in_industry | paper.changes_in_index | |
| common.calendar.number_days.1 | 7.93 $ | 0 $ | 0 $ | 0 % | 0 % | 0 % |
| common.calendar.number_days.7d | 8.31 $ | 0 $ | 0 $ | -4.57 % | 0 % | 0 % |
| common.calendar.number_days.30d | 7.87 $ | 7.93 $ | 8.43 $ | 0.76 % | 0 % | 0 % |
| common.calendar.number_days.90d | 5.01 $ | 5.01 $ | 8.43 $ | 58.28 % | 0 % | 0 % |
| common.calendar.number_days.180d | 6.66 $ | 5.01 $ | 8.43 $ | 19.07 % | 0 % | 0 % |
| common.calendar.number_days.1y | 5.44 $ | 3.99 $ | 8.43 $ | 45.77 % | 0 % | 0 % |
| common.calendar.number_days.3y | 6.98 $ | 3.99 $ | 11.61 $ | 13.61 % | 0 % | 0 % |
| common.calendar.number_days.5y | 9 $ | 3.89 $ | 11.61 $ | -11.89 % | 0 % | 0 % |
| common.calendar.number_days.10y | 0.287 $ | 0.287 $ | 14.33 $ | 2763.07 % | 0 % | 0 % |
| common.calendar.number_days.ytd | 6.5 $ | 5.01 $ | 8.43 $ | 22 % | 0 % | 0 % |
Principaux propriétaires
Entreprises similaires
P/E & P/BV
Gestion d'entreprise
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
| Mr. Rostislav Raykov | CEO & Director | 885.07k | 1976 (49 années) |
| Mr. Robert C. Andrade | Chief Financial Officer | 600.88k | 1975 (50 années) |
| Mr. Lei Fang | President of Pharstat Inc | N/A | |
| Mr. Mark Gowland | Controller |
Informations sur l'entreprise
Adresse: United States, Research Triangle Park. NC, 68 TW Alexander Drive - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.fennecpharma.com
Site web: https://www.fennecpharma.com
